Table 1:
Characteristics of patients who underwent EVAR, LVAD, and TAVR in Ontario and New York in 2012–2015*
| EVAR | LVAD | TAVR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ontario (N=3295) |
NY (N=6236) |
P-value | Ontario (N=136) |
NY (N=686) |
P-value | Ontario (N=1708) |
NY (N=4838) |
P-value | |
| Age, mean (sd) | 74.6 (9.1) | 74.5 (9.1) | 0.61 | 57.4 (12.7) | 57.7 (12.7) | 0.802 | 83.1 (7.7) | 83.1 (7.7) | 1 |
| Female, N(%) | 522 (15.8) | 1379 (22.1) | <.001 | 29 (21.3) | 143 (20.8) | 0.992 | 784 (45.9) | 2505 (51.8) | <.001 |
| Income Quintile 1 or 2 | 1300 (39.5) | 2195 (35.2) | <.001 | 58 (42.6) | 262 (38.2) | 0.380 | 625 (36.6) | 1060 (21.9) | <.001 |
| Income Quintile 3 | 653 (19.8) | 1137 (18.2) | 0.063 |
27 (19.9) | 112 (16.3) | 0.380 | 348 (20.4) | 713 (14.7) | <.001 |
| Income Quintile 4 or 5 | 1337 (40.6) | 2854 (45.8) | <.001 | 51 (37.5) | 305 (44.5) | 0.161 | 726 (42.5) | 3040 (62.8) | <.001 |
| Comorbid conditions | |||||||||
| Congestive heart failure | 82 (2.5) | 695 (11.1) | <.001 | 128 (94.1) | 672 (98.0) | 0.025 | 543 (31.8) | 3922 (81.1) | <.001 |
| Depression | 13 (0.4) | 420 (6.7) | <.001 | 11 (8.1) | 50 (7.3) | 0.884 | 9 (0.5) | 271 (5.6) | <.001 |
| Hypertension with complications | 10 (0.3) | 958 (15.4) | <.001 | 0 (0.0) | 174 (25.4) | <.001 | 9 (0.5) | 1399 (28.8) | <.001 |
| Diabetes without complications | 206 (6.3) | 1128 (18.1) | <.001 | SC† | 129 (18.8) | <.001 | 61 (3.6) | 1202 (24.8) | <.001 |
| COPD | 310 (9.4) | 1916 (30.7) | <.001 | 12 (8.8) | 277 (40.4) | <.001 | 156 (9.1) | 2289 (47.3) | <.001 |
| Renal Failure | 133 (4.0) | 998 (16.0) | <.001 | 17 (12.5) | 243 (35.4) | <.001 | 182 (10.7) | 1623 (33.5) | <.001 |
*
Each patient counted only once in each cohort (so a patient who underwent both TAVR and LVAD could appear once for each)
†
SC = small cells, cells <6 cannot be identified due to ICES privacy regulations